Sangamo Therapeutics, Inc. reported impairment results for the fourth quarter ended December 31, 2023. For the quarter, the company reported Impairment of long-lived assets of $0.3 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4448 USD | -1.27% |
|
-11.06% | -18.13% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.13% | 9.23Cr | |
+15.19% | 12TCr | |
+19.91% | 11TCr | |
+18.37% | 2.36TCr | |
-19.80% | 2.04TCr | |
-15.68% | 1.65TCr | |
-13.45% | 1.64TCr | |
-44.35% | 1.56TCr | |
+66.67% | 1.52TCr | |
+2.13% | 1.35TCr |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023